TELO
Telomir Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.23
+9.82%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 56.40x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 16.81x
- Price / sales
- —
- Price / cash flow
- -17.21x
Enterprise value
- Enterprise value
- $79.4M
- EV / sales
- —
- EV / EBITDA
- -13.53x
- EV / EBIT
- -13.05x
- Market cap
- $84.6M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026